Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05107674 · ClinicalTrials.gov registry record · Phase 1

A Study of NX-1607 in Adults With Advanced Malignancies

A Phase 1 study of Gastric Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by Nurix Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
345
Enrollment target
17
Study locations

NCT05107674: Recruiting Phase 1 study of Gastric Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by Nurix Therapeutics.

NCT05107674 is a Phase 1 study of Gastric Cancer and Head and Neck Squamous Cell Carcinoma that is actively recruiting participants, run by Nurix Therapeutics. The registered enrollment target is 345 participants, roughly in line with the 317-participant average among 153 other Gastric Cancer trials with a reported enrollment target. The trial reports 17 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05107674, a Phase 1 study of Gastric Cancer and Head and Neck Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Nurix Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
345 participants
Enrollment target
17
Study locations

Study Summary

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

Primary Outcome

Phase 1a

Conditions Studied

Gastric Cancer Head and Neck Squamous Cell Carcinoma Non-small Cell Lung Cancer (NSCLC) Metastatic Urothelial Carcinoma Metastatic Castration-Resistant Prostate Cancer (mCRPC) Triple Negative Breast Cancer (TNBC) GastroEsophageal Junction (GEJ) Cancer Malignant Pleural Mesothelioma (MPM) Ovarian Cancer, Epithelial Metastatic or Unresectable Melanoma

Interventions

  • DRUG Paclitaxel
  • DRUG NX-1607

Study Locations (17)

Other

  • Addenbrookes Cambridge University Hospital - Cambridge
  • Beatson West of Scotland Cancer Centre - Glasgow
  • Sarah Cannon Research Institute - London
  • The Christie NHS Foundation Trust - Manchester
  • Northern Centre for Cancer Care - Newcastle
  • Churchill Hospital - Oxford

California

  • City of Hope - Duarte
  • University of Southern California - Los Angeles
  • University of California, San Francisco - San Francisco

Colorado

  • University of Colorado School of Medicine - Aurora

Illinois

  • University of Chicago - Chicago

North Carolina

  • University of North Carolina - Chapel Hill

Oklahoma

  • University of Oklahoma - Oklahoma City

Texas

  • MD Anderson Cancer Center - Houston

Virginia

  • University of Virginia - Charlottesville

Trial Details

FieldValue
Enrollment Target 345 participants
Start Date 2021-09-29
Est. Completion 2028-02-28
Phase Phase 1
Nurix Therapeutics

8 total trials

What NCT05107674 shows while recruiting

NCT05107674 is an interventional study that assigns participants to a tested intervention. The registered 345 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 317-participant average among 153 other Gastric Cancer trials with a reported enrollment target.

The record links to 10 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.

NCT05107674 lists 17 locations in 10 states (Other, California, Colorado).

Frequently Asked Questions

What is clinical trial NCT05107674 about?

NCT05107674 is a clinical study titled "A Study of NX-1607 in Adults With Advanced Malignancies". This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

What is the current status of trial NCT05107674?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 345 participants. The study started on 2021-09-29. Estimated completion is 2028-02-28.

What conditions does trial NCT05107674 study?

This clinical trial studies the following conditions: Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Urothelial Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC).

What interventions are being tested in trial NCT05107674?

The interventions under investigation include: Paclitaxel (DRUG), NX-1607 (DRUG).

Who is sponsoring clinical trial NCT05107674?

This trial is sponsored by Nurix Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05107674 being conducted?

This trial has 17 study locations across California, Colorado, Illinois, North Carolina, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05107674's enrollment target sits among peer trials

345 35th of 153 higher than 119 of 153 other Gastric Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03972657 · 345 participants · Phase 1

    A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

  • NCT05700279 · 345 participants · NA

    Preventing the Development of Chronic Pain: Treating PTSD at Acute Pain Onset

  • NCT05781100 · 345 participants · NA

    Investigating Baby Behavior and Family Technology Use Study

  • NCT06884618 · 345 participants · Phase 1

    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05107674

Source: ClinicalTrials.gov NCT05107674, the US trial registry maintained by the National Library of Medicine. NCT05107674 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.